MANGALAM Stock Overview
Together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mangalam Drugs & Organics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹114.76 |
| 52 Week High | ₹144.99 |
| 52 Week Low | ₹90.80 |
| Beta | 0.78 |
| 1 Month Change | 9.27% |
| 3 Month Change | -9.90% |
| 1 Year Change | 16.45% |
| 3 Year Change | -3.07% |
| 5 Year Change | 313.55% |
| Change since IPO | 856.33% |
Recent News & Updates
Recent updates
Additional Considerations Required While Assessing Mangalam Drugs & Organics' (NSE:MANGALAM) Strong Earnings
Nov 22
Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors
Aug 13A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
May 23Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Oct 20Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Mar 29These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively
May 31A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Apr 06We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt
Jan 03Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly
May 23Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Jan 04Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?
Nov 12
A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Sep 20Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?
Aug 05We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt
Jul 01Shareholder Returns
| MANGALAM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.3% | 0.8% | -4.3% |
| 1Y | 16.4% | 39.7% | 19.1% |
Return vs Industry: MANGALAM underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: MANGALAM underperformed the Indian Market which returned 19.1% over the past year.
Price Volatility
| MANGALAM volatility | |
|---|---|
| MANGALAM Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: MANGALAM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: MANGALAM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 432 | Govardhan Dhoot | www.mangalamdrugs.com |
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers API products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; and ortho phenoxy methane sulfonanilide, tenofovir alafenamide base, and tenofovir disoproxil base.
Mangalam Drugs & Organics Limited Fundamentals Summary
| MANGALAM fundamental statistics | |
|---|---|
| Market cap | ₹1.82b |
| Earnings (TTM) | ₹94.03m |
| Revenue (TTM) | ₹3.55b |
19.3x
P/E Ratio0.5x
P/S RatioIs MANGALAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MANGALAM income statement (TTM) | |
|---|---|
| Revenue | ₹3.55b |
| Cost of Revenue | ₹2.12b |
| Gross Profit | ₹1.44b |
| Other Expenses | ₹1.34b |
| Earnings | ₹94.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 5.94 |
| Gross Margin | 40.41% |
| Net Profit Margin | 2.65% |
| Debt/Equity Ratio | 61.6% |
How did MANGALAM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mangalam Drugs & Organics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijay Madunala | FirstCall Research |